The Weekly Summary

ebola-doctorOctober 20th – October 26th

In the general news, Syria ISIS terrorists inspired homeland attacks in Ottawa, Canada, and also in New York City. However, those events were overshadowed in the news by the case of Ebola in New York, in a doctor traveling from Africa who is now being treated at Bellevue. State governors then defied the federal government and imposed their own plans to quarantine travelers flying in from Africa.

In healthcare news, earnings season continued with Edwards (EW) turning the corner and showing huge growth in Sapien TAVR numbers. Boston Scientific’s (BSX) S-ICD was approved by Aetna. In biotech, activist Dan Loeb wants to break up Amgen (AMGN) into legacy and new drug divisions. Celgene (CELG) partnered with Sutro Biopharma with an option to buy. Lastly, TesoRX licensed away it’s Low-T drug to Aspen as the FDA tighten the prescribing label indications.

From the FDA, Dexcom’s (DXCM) received approval for its SHARE smartphone app. Baxter (BAX) won approval for hemophilia drug Obizur. Lastly, a panel backed Novartis’ (NVS) psoriasis drug secukinumab.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.